15.07.2016 • NewsDede WillamsTuring Pharmaceuticalsfraud

Shkreli’s Fraud Trial Set for June 2017

(c) arturbo
(c) arturbo

A US federal judge has set Jun. 26, 2017 as the trial date for Martin Shkreli, the 33-year-old founder of Retrophin and Turing Pharmaceuticals and former CEO of KalaBios as well as a hedge fund, on charges of securities fraud.

Shkreli was arrested in December 2015 on charges he defrauded investors in hedge funds he ran and used $11 million worth of Retrophin assets to pay them off and also hid control of unrestricted stock in the company, which he allegedly used to pay down debt.

While at Turing, the former CEO also came under scrutiny for jacking up the price of Daraprim (pyrimethamine), a 62-year-old drug used to treat the deadly parasitic infection toxoplasmosis, from $13.50 to $700 a tablet shortly after acquiring marketing rights in August of last year.

Shkreli has pleaded “not guilty” to all of the charges. Reports said the US government had been hoping to begin the trial by February of next year; however, an attorney being charged as Shkreli’s accomplice had asked for a postponement until September or October 2017. Both defendants may opt to pursue separate trials, depending on the defense’s strategy.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.